Allogene is ceasing enrollment in a Phase I trial of cema-cel for patients with relapsed or refractory chronic lymphocytic ...
Key Insights Significantly high institutional ownership implies Bristol-Myers Squibb's stock price is sensitive ...
GSK’s 3 billion pounds sterling peak sales goal for its multiple myeloma drug Blenrep appears increasingly attainable thanks ...
Allogene Therapeutics has dropped plans to target one of its allogeneic CAR-Ts at leukemia in the face of competition from ...
LOUISVILLE, Ky. -- More than half of patients with newly diagnosed metastatic kidney cancer responded to a novel drug ...
Gabriele Ricci, chief data and technology officer, has been reorganizing the technology function at Takeda Pharmaceutical.
As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...
Bearish flow noted in Bristol Myers (BMY) Squibb with 6,501 puts trading, or 1.1x expected. Most active are Nov-24 59 puts and 11/29 weekly 50 puts, with total volume in those strikes near 3,400 ...
Adding a PD-1 inhibitor to standard of care improved disease-free survival (DFS) in stage III soft-tissue sarcoma of the ...
On Tuesday, Bristol-Myers Squibb Co (BMY) stock saw a decline, ending the day at $59.02 which represents a decrease of $-0.80 or -1.34% from the prior close of $59.82. The stock opened at $59.82 and ...
Shares of Bristol Myers Squibb Co. BMY shed 1.34% to $59.02 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 0.29% to 5,983.99 ...
BMO Capital analyst Evan Seigerman raised the firm’s price target on Bristol Myers (BMY) to $61 from $57 and keeps a Market Perform ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback